Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD

0
20
Outlook Therapeutics, Inc. announced that the European Commission has granted Marketing Authorization for LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD) in the EU.
[Outlook Therapeutics, Inc.]
Press Release